334 related articles for article (PubMed ID: 28530524)
1. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
[TBL] [Abstract][Full Text] [Related]
2. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
[TBL] [Abstract][Full Text] [Related]
3. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
4. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
[TBL] [Abstract][Full Text] [Related]
5. Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges.
Perfetto EM; Anyanwu C; Pickering MK; Zaghab RW; Graff JS; Eichelberger B
J Manag Care Spec Pharm; 2016 Jun; 22(6):609-16. PubMed ID: 27231789
[TBL] [Abstract][Full Text] [Related]
6. Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up.
Augustine J; Warholak TL; Hines LE; Sun D; Brown M; Hurwitz J; Taylor AM; Brixner D; Cobaugh DJ; Schlaifer M; Malone DC
J Manag Care Spec Pharm; 2016 Jun; 22(6):618-25. PubMed ID: 27231790
[TBL] [Abstract][Full Text] [Related]
7. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
8. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.
Park Y; Raza S; George A; Agrawal R; Ko J
J Manag Care Spec Pharm; 2017 Aug; 23(8):893-901. PubMed ID: 28737993
[TBL] [Abstract][Full Text] [Related]
11. The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness.
Dreyer NA; Bryant A; Velentgas P
J Manag Care Spec Pharm; 2016 Oct; 22(10):1107-13. PubMed ID: 27668559
[TBL] [Abstract][Full Text] [Related]
12. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
Panzer AD; Margaretos NM; Lai RC; Enright DE; Chambers JD
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1307-1311. PubMed ID: 32212282
[TBL] [Abstract][Full Text] [Related]
13. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
16. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
[No Abstract] [Full Text] [Related]
17. Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
Lee W; Dayer V; Jiao B; Carlson JJ; Devine B; Veenstra DL
J Manag Care Spec Pharm; 2021 Jan; 27(1):5-14. PubMed ID: 33377439
[No Abstract] [Full Text] [Related]
18. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
19. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
